Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 4 of 4 results for herceptin

  1. Price discount helps give green light for breast cancer drug pertuzumab

    NICE approves the third breast cancer drug is as many weeks as pertuzumab is recommended to shrink tumours in some people with breast cancer so surgery can take place.

    News
    Published
    17 November 2016

  2. Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab (ESNM13)

    Summary of the evidence on subcutaneous trastuzumab for HER2-positive breast cancer to inform local NHS planning and decision-making

    Evidence summary
    Published
    13 March 2013

  3. Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 (TA257)

    Evidence-based recommendations on lapatinib (Tyverb) and trastuzumab (Herceptin) for treating metastatic hormone receptor-positive breast cancer that overexpresses HER2 in adults.

    Technology appraisal guidance
    Published
    27 June 2012
    View recommendations

    Sections for TA257

  4. Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208)

    Evidence-based recommendations on trastuzumab (Herceptin) for treating HER2-positive metastatic gastric cancer in adults.

    Technology appraisal guidance
    Published
    24 November 2010
    View recommendations

    Sections for TA208